You are here

Michael Gale Jr., PhD

Severity of virus infection is attributed in part to viral control of host cell innate immune programming and viral evasion of the host immune response. Understanding these processes will facilitate the development of antiviral therapeutics. 

Office E383, Box 358059 750 Republican Street Seattle WA 98195-8059
(206) 543-8514

Lab Staff

Aimee McMillan
Al Huang
Alison Kell
Alvin Tan
Amina Negash
Amy Stone
Conor Selleck
Courtney Wilkins
Gabriele Blahnik
Jill Wang
John Errett
Jonathan Florentin
Kwan Chow
Maggie Brassil
Michael Davis
Nanette Crochet
Ran Dong
Renee Ireton
Russell Barlow
Sowmya Pattabhi
Sunil Thomas
Tien-Ting Hsiang
Yueh-Ming Loo
Michael Gale Jr., PhD
CERID Co-Director. Professor, Immunology; Adjunct Professor, Microbiology and Global Health; Member, FHCRC/UW Cancer Consortium

Research in the Gale laboratory is focused on 1) understanding the basis of non-self discrimination and immune response triggering by emerging RNA viruses, 2) Defining the virus and host interactions that trigger and control innate antiviral immune defenses, 3) Identifying therapeutic targets for induction and enhancement of innate immunity against RNA virus infection, 4) Discovery and development of small molecule therapeutics as vaccine adjuvants and for the treatment of viral infection, and 5) Development of vaccines for protection against emerging RNA viruses. The lab works very closely Kineta, a Seattle Biopharmaceutical company to translate and develop therapeutics against RNA viruses.

Hepatitis C virus

Description: The figure depicts hepatitis C virus.
Innate Immune signaling by RNA viruses. Michael Gale Jr. et al. (2005) Nature 436: 939-940)